BioCentury
ARTICLE | Company News

Samsung Bioepis partners with AffaMed, expands biosimilar development in China

February 15, 2019 6:14 PM UTC

Samsung Bioepis Co. Ltd. (Incheon, South Korea) partnered to develop four of its biosimilars with AffaMed Therapeutics (Shanghai, China). The partners will initially collaborate on clinical development, regulatory registration and commercialization Ontruzant, SB11, SB12 and an undisclosed candidate in China with the possibility of expanding to other biosimilars and innovative drugs.

Samsung Bioepis will receive an undisclosed upfront payment and is eligible for royalties...

BCIQ Company Profiles

Samsung Bioepis Co. Ltd.